Search results
Results from the WOW.Com Content Network
Treatment using these targets can supplement or replace some of the intensive chemotherapy that is used for neuroblastoma. These molecular targets of this disease include GD2 , ALK , and CD133 . GD2 is a target of immunotherapy , and is the most fully developed of these treatment methods, but is also associated with toxicities. [ 1 ]
Dinutuximab (Ch14.18, tradename Unituxin) and dinutuximab beta (tradename Qarziba) are monoclonal antibodies used as a second-line treatment for children with high-risk neuroblastoma. Each antibody is made of both mouse and human components and targets glycolipid GD2 , expressed on neuroblastoma cells and on normal cells of neuroectodermal ...
By contrast, focus the past 20 years or more has been to intensify treatment for high-risk neuroblastoma. Chemotherapy induction variations, timing of surgery, stem cell transplant regimens, various delivery schemes for radiation, and use of monoclonal antibodies and retinoids to treat minimal residual disease continue to be examined.
The degree of differentiation of neuroblastoma is correlated to the prognosis, with a wide variety of outcomes (from tumor regression to recurrence and mortality). The standard of care is the use of chemotherapy, surgical resection and radiation, although most aggressive neuroblastomas have demonstrated to be resistant to these therapies.
Chemotherapy is used in a multimodality treatment plan generally for more advanced, unresectable or reoccurring tumors. [4] Cyclophosphamide, vincristine and doxorubicin have been used as neoadjuvant chemotherapy drugs for grade C esthesioneuroblastoma before surgical resection, producing fair outcomes.
Complete or partial treatment response has been seen in 20-30% of patients in trials treated with 177 Lu-DOTATATE or 90 Y-DOTATOC, among the most widely used PRRT drugs. [ 1 ] [ 11 ] [ 12 ] [ 13 ] When it comes to comparing these two PRRT, Y-labeled and Lu-labeled PRRTs, it appears that Y-labeled is more effective for larger tumors, while Lu ...
Since neurologic and developmental difficulties have not been reported as a consequence of neuroblastoma or its treatment, it is thought that these are exclusively due to the immune mechanism underlying OMS. [24] One study concludes that: "Patients with OMA and neuroblastoma have excellent survival but a high risk of neurologic sequelae ...
In general, treatment can include surgical resection, [39] chemotherapy, [40] radiation therapy, [41] or immunotherapy. [42] Recent medical advances have improved our understanding of the genetic basis of childhood cancers. Treatment options are expanding, and precision medicine for childhood cancers is a rapidly growing area of research. [43]